BrainsWay Ltd. (BRSYF)
| Market Cap | 613.20M +172.6% |
| Revenue (ttm) | 56.22M +29.4% |
| Net Income | 8.76M +123.6% |
| EPS | 0.22 +176.9% |
| Shares Out | n/a |
| PE Ratio | 70.02 |
| Forward PE | 43.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 15.13 |
| Previous Close | 15.13 |
| Day's Range | 13.54 - 15.13 |
| 52-Week Range | 5.49 - 16.84 |
| Beta | 0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial StatementsNews
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.
BrainsWay Ltd (BWAY) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 65/100
BrainsWay Ltd (BWAY) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 65/100
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to active...
Brainsway initiated with a Buy at BTIG
BTIG initiated coverage of Brainsway (BWAY) with a Buy rating and $18 price target The company has demonstrated the ability to scale a transcranial magnetic stimulation business into sustainable profi...
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports Brai...
BrainsWay (BWAY) Shares Positive Results from Real-World Study on PTSD and Depression
BrainsWay (BWAY) Shares Positive Results from Real-World Study on PTSD and Depression
Brainsway presents new Deep Transcranial Magnetic Stimulation data
BrainsWay (BWAY) announced the presentation of new real-world data demonstrating significant improvements in patients with comorbid post-traumatic stress disorder and Major Depressive Disorder treated...
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTS...
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals O...
Brainsway price target raised to $17 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $17 from $15 and keeps a Buy rating on the shares following the Q1 report. The…
Brainsway announces $1.5M investment in APS Innovations
BrainsWay (BWAY) announced it has entered into a strategic equity financing agreement with APS Innovations, the parent company of Advanced Psychiatric Management, a management services organization se...
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access t...
Brainsway Q1 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recur...
BrainsWay Earnings Call Transcript: Q1 2026
Revenue rose 35% year-over-year to $15.5M, with net income more than doubling and strong growth in Deep TMS system placements. Expanded payer coverage, strategic investments, and robust international demand support a positive outlook, with 2026 revenue guidance of $66–$68M.
BrainsWay Earnings release: Q1 2026
BrainsWay released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Brainsway reports Q1 EPS 6c, consensus 5c
Reports Q1 revenue $15.53M, consensus $14.62M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
Brainsway backs FY26 revenue view $66M-$68M, consensus $66.44M
Backs FY26 adjusted EBITDA view $12M-$14M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation techno...
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administratio...
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Brainsway completes revenue-based milestone investment into Axis Integrated
BrainsWay (BWAY) has completed a $1M milestone-based investment in Axis Integrated Mental Health, a management services organization servicing several mental health clinics in Colorado. The investment...